Interestingly, some clues can be found from a number of recent studies on mTOR inhibitors that eradicated the CSC populations in nasopharyngeal carcinoma, colon cancer, and glioblastoma multiforme, among other cancers (Francipane and Lagasse, 2013; Sami and Karsy, 2013; Kolev et al., 2015; Yang et al., 2015), which may indicate future directions for designing novel drugs targeting mTOR for renal CSCs. This evidence concerns the gene MTOR and cancer.